Non-invasive Interrogation of DLL3 Expression in Metastatic Small Cell Lung Cancer

The Notch ligand DLL3 has emerged as a novel therapeutic target expressed in small cell lung cancer (SCLC) and high-grade neuroendocrine carcinomas. Rovalpituzumab teserine (Rova-T™; SC16LD6.5) is a first-in-class DLL3-targeted antibody-drug conjugate with encouraging initial safety and efficacy pro...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Res
Main Authors: Sharma, Sai Kiran, Pourat, Jacob, Abdel-Atti, Dalya, Carlin, Sean D., Piersigilli, Alessandra, Bankovich, Alexander J., Gardner, Eric E., Hamdy, Omar, Isse, Kumiko, Bheddah, Sheila, Sandoval, Joseph, Cunanan, Kristen M., Johansen, Eric B., Allaj, Viola, Sisodiya, Vikram, Liu, David, Zeglis, Brian M., Rudin, Charles M., Dylla, Scott J., Poirier, John T., Lewis, Jason S.
Formato: Artigo
Idioma:Inglês
Publicado em: 2017
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5534176/
https://ncbi.nlm.nih.gov/pubmed/28487384
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-17-0299
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados